|
1
|
Chen S, Leitao MM, Tornos C and Soslow RA:
Invasion patterns in stage I endometrioid and mucinous ovarian
carcinomas: A clinicopathologic analysis emphasizing favorable
outcomes in carcinomas without destructive stromal invasion and the
occasional malignant course of carcinomas with limited destructive
stromal invasion. Mod Pathol. 18:903–911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prowse AH, Manek S, Varma R, Liu J, Godwin
AK, Maher ER, Tomlinson IP and Kennedy SH: Molecular genetic
evidence that endometriosis is a precursor of ovarian cancer. Int J
Cancer. 119:556–562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreno-Bueno G, Gamallo C, Pérez-Gallego
L, de Mora JC, Suárez A and Palacios J: Beta-catenin expression
pattern, beta-catenin gene mutations, and microsatellite
instability in endometrioid ovarian carcinomas and synchronous
endometrial carcinomas. Diagn Mol Pathol. 10:116–122. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sagae S, Kobayashi K, Nishioka Y, Sugimura
M, Ishioka S, Nagata M, Terasawa K, Tokino T and Kudo R: Mutational
analysis of beta-catenin gene in Japanese ovarian carcinomas:
Frequent mutations in endometrioid carcinomas. Jpn J Cancer Res.
90:510–515. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wright K, Wilson P, Morland S, Campbell I,
Walsh M, Hurst T, Ward B, Cummings M and Chenevix-Trench G:
Beta-catenin mutation and expression analysis in ovarian cancer:
Exon 3 mutations and nuclear translocation in 16% of endometrioid
tumours. Int J Cancer. 82:625–629. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu R, Hendrix-Lucas N, Kuick R, Zhai Y,
Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO,
et al: Mouse model of human ovarian endometrioid adenocarcinoma
based on somatic defects in the Wnt/beta-catenin and PI3K/Pten
signaling pathways. Cancer Cell. 11:321–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu R, Zhai Y, Fearon ER and Cho KR:
Diverse mechanisms of beta-catenin deregulation in ovarian
endometrioid adenocarcinomas. Cancer Res. 61:8247–8255.
2001.PubMed/NCBI
|
|
8
|
Catasus L, Bussaglia E, Rodrguez I,
Gallardo A, Pons C, Irving JA and Prat J: Molecular genetic
alterations in endometrioid carcinomas of the ovary: Similar
frequency of beta-catenin abnormalities but lower rate of
microsatellite instability and PTEN alterations than in uterine
endometrioid carcinomas. Hum Pathol. 35:1360–1368. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Obata K, Morland SJ, Watson RH, Hitchcock
A, Chenevix-Trench G, Thomas EJ and Campbell IG: Frequent PTEN/MMAC
mutations in endometrioid but not serous or mucinous epithelial
ovarian tumors. Cancer Res. 58:2095–2097. 1998.PubMed/NCBI
|
|
10
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell IG, Russell SE, Choong DY,
Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and
Phillips WA: Mutation of the PIK3CA gene in ovarian and breast
cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwartz DR, Kardia SL, Shedden KA, Kuick
R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et
al: Gene expression in ovarian cancer reflects both morphology and
biological behavior, distinguishing clear cell from other
poor-prognosis ovarian carcinomas. Cancer Res. 62:4722–4729.
2002.PubMed/NCBI
|
|
13
|
Tashiro H, Blazes MS, Wu R, Cho KR, Bose
S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
|
14
|
Risinger JI, Hayes AK, Berchuck A and
Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer
Res. 57:4736–4738. 1997.PubMed/NCBI
|
|
15
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:375–378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Myers MP, Pass I, Batty IH, Van der Kaay
J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP and Tonks NK: The
lipid phosphatase activity of PTEN is critical for its tumor
supressor function. Proc Natl Acad Sci USA. 95:13513–13518. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Downward J: Ras signalling and apoptosis.
Curr Opin Genet Dev. 8:49–54. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sif S, Saurin AJ, Imbalzano AN and
Kingston RE: Purification and characterization of mSin3A-containing
Brg1 and hBrm chromatin remodeling complexes. Genes Dev.
15:603–618. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, Xue Y, Zhou S, Kuo A, Cairns BR
and Crabtree GR: Diversity and specialization of mammalian SWI/SNF
complexes. Genes Dev. 10:2117–2130. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reisman D, Glaros S and Thompson EA: The
SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang H, Cheung LW, Li J, Ju Z, Yu S,
Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome
sequencing combined with functional genomics reveals novel
candidate driver cancer genes in endometrial cancer. Genome Res.
22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roth LM, Emerson RE and Ulbright TM:
Ovarian endometrioid tumors of low malignant potential: A
clinicopathologic study of 30 cases with comparison to
well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol.
27:1253–1259. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bell KA and Kurman RJ: A clinicopathologic
analysis of atypical proliferative (borderline) tumors and
well-differentiated endometrioid adenocarcinomas of the ovary. Am J
Surg Pathol. 24:1465–1479. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jetley S, Khetrapal S, Ahmad A and
Jairajpuri ZS: Atypical proliferative endometrioid tumor of ovary:
Report of a rare case. J Postgrad Med. 62:129–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levine RL, Cargile CB, Blazes MS, van Rees
B, Kurman RJ and Ellenson LH: PTEN mutations and microsatellite
instability in complex atypical hyperplasia, a precursor lesion to
uterine endometrioid carcinoma. Cancer Res. 58:3254–3258.
1998.PubMed/NCBI
|
